Pimavanserin treatment increases plasma brain-derived neurotrophic factor levels in rats
BackgroundPimavanserin, a serotonin 5HT-2A receptor inverse agonist is the first-line, FDA-approved treatment of hallucinations and delusions associated with Parkinson’s Disease psychosis (PDP), which occurs in up to 50% of PD patients. The neurobiological mechanism underlying the therapeutic effect...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Frontiers Media S.A.
2023-08-01
|
| Colección: | Frontiers in Neuroscience |
| Materias: | |
| Acceso en línea: | https://www.frontiersin.org/articles/10.3389/fnins.2023.1237726/full |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|